EXCLUSIVE: Pelthos Acquires Antimicrobial Drug Rights and Raises $18 Million for Commercial Launch Support
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 07 2025
0mins
Source: Benzinga
Acquisition of Xepi: Pelthos Therapeutics Inc. has acquired U.S. commercialization rights to Xepi (ozenoxacin) Cream from Biofrontera Inc. and Ferrer Internacional S.A. for a total of $4.2 million, with plans to relaunch the product in late 2026.
Product Details: Xepi is a topical antimicrobial treatment for impetigo, a contagious skin infection affecting around 3 million people in the U.S. annually, particularly children aged 2 to 5.
Funding for Commercialization: Pelthos has secured $18 million in private convertible notes financing to support the acquisition and relaunch of Xepi, as well as to accelerate the commercialization of another product, Zelsuvmi.
Market Response: Following the acquisition announcement, Pelthos Therapeutics shares remained stable at $37.42 during premarket trading, indicating limited movement in the stock price.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like LGND with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on LGND
Wall Street analysts forecast LGND stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LGND is 243.50 USD with a low forecast of 220.00 USD and a high forecast of 275.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 190.220
Low
220.00
Averages
243.50
High
275.00
Current: 190.220
Low
220.00
Averages
243.50
High
275.00
About LGND
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
S&P 500 and Dow Reverse Gains as Nasdaq Narrows Upturn
- Market Volatility: On Wednesday, the S&P 500 and Dow reversed from their highs, indicating a shift in market sentiment that could influence short-term investor decisions.
- Nasdaq Performance: Although the Nasdaq index initially gained, it ultimately narrowed its gains, reflecting the volatility of tech stocks and the uncertainty in the market.
- Buy Signals: Eli Lilly and Google flashed buy signals, potentially attracting investor interest in these companies' future growth prospects, especially in the current market environment.
- Investor Sentiment: The overall market reversal may lead investors to reassess their risk appetite, thereby affecting capital flows and market dynamics.
Continue Reading
S&P 500 and Dow Retreat from Highs, Eli Lilly and Google Flash Buy Signals
- Market Volatility: On Wednesday, the S&P 500 and Dow retreated from their highs, indicating a shift in market sentiment that could influence short-term investor decisions and risk appetite.
- Nasdaq Performance: Although the Nasdaq index pared gains, it still shows potential for growth, suggesting that volatility in tech stocks may provide short-term trading opportunities for investors.
- Buy Signals: Stocks of Eli Lilly and Google flashed buy signals, potentially attracting investor attention to the growth prospects of these companies in their respective sectors, which could drive their stock prices higher.
- Investor Strategy Adjustment: The market fluctuations and buy signals may prompt investors to reassess their portfolios, particularly in the current economic environment, seeking more promising investment opportunities.
Continue Reading